Pressemeddelelse -
Trastuzumab Deruxtecan Recommended for Conditional Marketing Authorization in the EU by CHMP for HER2 Positive Metastatic Breast Cancer
Trastuzumab Deruxtecan Recommended for Conditional Marketing Authorization in the EU by CHMP for HER2 Positive Metastatic Breast Cancer
Recommendation based on positive results from the DESTINY-Breast01 trial, which showed durable responses in patients with previously treated disease
Tokyo and Munich – (December 11, 2020) – Daiichi Sankyo Company, Limited(hereafter, Daiichi Sankyo) and AstraZeneca’s trastuzumab deruxtecan has been recommended for conditional marketing authorization in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2 based regimens.
See attached press release
Emner
- Sundhed, sundhedsvæsen, lægemidler
Kategorier
- cancer
- studier
- onkologi
- oncology
- breast cancer
- brystkræft
- sabcs
- mbc
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
Through the outstanding knowledge and commitment of our 15,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.
